The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)

  • Lowest Price Guaranteed From USD 4,499

  • Published
    October 2019

  • Pages
    558

  • View Count
    8694

Example Insights

Vector and Gene Therapy Manufacturers-Context Vector and Gene Therapy Manufacturers-Distribution by respondents Vector and Gene Therapy Manufacturers-Different type of viral & non-viral vectors
Vector and Gene Therapy Manufacturers-Manufacturing different vectors Vector and Gene Therapy Manufacturers-Distribution by location of manufacturing facility Vector and Gene Therapy Manufacturers-Partnerships & Collaborations
Vector and Gene Therapy Manufacturers-Capacity Analysis Vector and Gene Therapy Manufacturers-Viral & Non-viral vectors Vector and Gene Therapy Manufacturers-Upcoming Vectors
Vector and Gene Therapy Manufacturers-Market Forecast Vector and Gene Therapy Manufacturers-Distribution by market share  

 

Overview

Over the last 12 months, the pharmaceutical industry reported a year-on-year increment of nearly 75% in funding to support the development of various cell and gene therapies. In fact, close to USD 5 billion has been invested into research on gene-based therapies in the previous two decades. Interestingly, over 2,600 clinical studies have been initiated in this field of research, since 1989. The aforementioned numbers are indicative of the rapid pace of development in this upcoming segment of the biopharmaceutical industry. The development of such therapy products require gene delivery vehicles, called vectors, to desired locations within the body (in vivo) / specific cells (ex vivo). The growing demand for such therapies and the rising number of clinical research initiatives in this domain has led to an increase in demand for preclinical and clinical grade gene delivery vectors. Fundamentally, genetic modifications can be carried out using either viral (such as adenovirus, adeno associated virus (AAV), lentivirus, retrovirus, Sendai virus, herpes simplex virus, vaccinia virus, baculovirus and alphavirus) or non-viral (such as plasmid DNA) vectors. Moreover, recent advances in vector research have led to the development of several innovative viral / non-viral gene delivery approaches.

At present, 10+ genetically modified therapies have received approval / conditional approval in various regions of the world; these include (in the reverse chronological order of year of approval) Zynteglo™ (2019), Zolgensma® (2019), Collategene® (2019), LUXTURNA™ (2017), YESCARTA™ (2017), Kymriah™ (2017), INVOSSA™ (2017), Zalmoxis® (2016), Strimvelis™ (2016), Imlygic® (2015), Neovasculagen® (2011), Rexin-G® (2007), Oncorine® (2005) and Gendicine® (2003). In addition, over 500 therapy candidates are being investigated across different stages of development. The growing number of gene-based therapies, coupled to their rapid progression through the drug development process, has created significant opportunities for companies with expertise in vector manufacturing. Presently, a number of industry (including both well-established companies and smaller R&D-focused initiatives), and non-industry players (academic institutes) claim to be capable of manufacturing different types of viral and non-viral vectors. In addition, there are several players offering novel technology solutions, which are capable of improving existing genetically modified therapy products and upgrading their affiliated manufacturing processes. Considering prevalent and anticipated future trends, we believe that the vector and gene therapy manufacturing market is poised to grow steadily, driven by a robust pipeline of therapy candidates and technical advances aimed at mitigating existing challenges related to gene delivery vector and advanced therapy medicinal products. In addition, due to the ongoing COVID-19 crisis, pharmaceutical companies have taken high priority development initiatives related to vaccines based on viral vectors; we anticipate this to substantially increase the demand for manufacturing services of viral vectors in the near future.

Scope of the Rpeort

The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)” report features an extensive study of the rapidly growing market of viral and non-viral vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies with in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • An overview of the current status of the market with respect to the players involved (both industry and non-indutry) in manufacturing viral vectors, non-viral vectors and other novel types of vectors. It features information on the year of establishment, scale of production, type of vectors manufactured, location of manufacturing facilities, applications of vectors (in gene therapy, cell therapy, vaccines and others), and purpose of production (fulfilling in-house requirements / for contract services).
  • An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • An estimate of the overall, installed vector manufacturing capacity of industry players based on information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by vector type (viral vector and plasmid DNA), scale of operation (clinical and commercial), size of the company / organization (small-sized, mid-sized and large) and key geographical regions (North America, Europe, Asia Pacific and the rest of the world).
  • An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations; namely [A] a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and purpose of production (in-house operations and contract manufacturing services), [B] a logo landscape of viral vector and plasmid DNA manufacturers based on the type (industry and non-industry) and the size of the industry player (small-sized, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of vector manufacturing hubs.
  • An analysis of recent collaborations  and partnership agreements inked in this domain since 2015; it includes details of deals that were / are focused on the manufacturing of vectors, whihc were analyzed on the basis of year of agreement, type of agreement, type of vector involved, and scale of operation (laboratory, clinical and commercial). 
  • An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of proprietary vectors.
  • An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on scale of operation). Each profile features an overview of the company / organization, its financial performance (if available), information on its manufacturing facilities, vector manufacturing technology and an informed future outlook.
  • A discussion on the factors driving the market and the various challenges associated with the vector production process.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the vector manufacturing market, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies, anticipated growth in target patient population, existing price variations across different vector types, and the anticipated success of gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of  [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. For the purpose of the study, we invited over 160 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions held with several key players in this domain. The report features detailed transcripts of interviews held with the stakeholders:

  • Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
  • Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
  • Joost van den Berg (Director, Amsterdam BioTherapeutics Unit)
  • Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
  • Colin Lee Novick (Managing Director, CJ Partners)
  • Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
  • Semyon Rubinchik (Scientific Director, ACGT)
  • Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes)
  • Alain Lamproye (President of Biopharma Business Unit, Novasep)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)
  • Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)
  • Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vehicles. The chapter also provides a brief description of the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market. 

Chapter 4 provides a detailed overview of around 80 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, scale of production, type of viral vectors manufactured (AAV, adenoviral, lentiviral, retroviral and others), location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of production (fulfilling in-house requirements / for contract services). 

Chapter 5 provides an overview of around 30 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 6 provides an overview of around 80 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, type of vectors manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others), applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 7 features detailed profiles of the US based contract service providers / in-house manufacturers that possess commercial scale capacities for the production of viral vectors / plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 8 features detailed profiles of EU based contract service providers / in-house manufacturers that possess commercial scale capacities for the production of viral vectors / plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 9 features detailed profiles of Asia-Pacific based contract service provider(s) / in-house manufacturer(s) that possess commercial scale capacities for production of viral vectors / plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 10 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus based vectors, Sendai virus based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development / manufacturing of some of these novel vectors. 

Chapter 11 features an elaborate analysis and discussion of the various collaborations and partnerships related to the manufacturing of vectors or gene therapies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers / acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2015. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid DNA manufacturers based on the type of organization (industry / non-industry) and size of employee base. The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the locations of global vector manufacturing hubs across different continents. 

Chapter 13 highlights our views on the various factors that may be taken into consideration while pricing viral vectors / plasmid DNA. It features discussions on different pricing models / approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.

Chapter 14 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations across different types of vectors (viral vectors, plasmid DNA, and both), scale of operation (clinical and commercial) and geographies (North America, EU, Asia-Pacific and the rest of the world).

Chapter 15 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analysed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 16 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 17 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.

Chapter 18 presents insights from the survey conducted on over 160 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 19 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 20 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Olivier Boisteau, (Co-Founder / President, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Colin Lee Novick (Managing Director, CJ Partners), Cedric Szpirer (Executive & Scientific Director, Delphi Genetics), Semyon Rubinchik (Scientific Director, ACGT), Eduard Ayuso (Scientific Director, Translational Vector Core, University of Nantes), Alain Lamproye (President of Biopharma Business Unit, Novasep), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory), Nicolas Grandchamp (R&D Leader, GEG Tech) and Beatrice Araud  (ATMP Key Account Manager, EFS-West Biotherapy). 

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Methods of Gene Transfer
3.3. Viral Vectors for Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus

3.5. Types of Non-Viral Vectors
3.5.1. Plasmid DNA
3.5.2. Liposomes, Lipoplexes and Polyplexes
3.5.3. Oligonucleotides
3.5.4. Other Non-Viral Vectors
3.5.5. Gene Delivery using Non-Viral Vectors
3.5.5.1. Biolistic Methods
3.5.5.2. Electroporation
3.5.5.3. Receptor Mediated Gene Delivery
3.5.5.4. Gene Activated Matrix (GAM)

3.6. Applications of Viral and Non-Viral Vectors
3.6.1. Type of Therapy
3.6.1.1. Cell and Gene Therapy
3.6.1.2. Vaccinology

3.7. Current Trends in Vector Development / Manufacturing
3.7.1. Vector Engineering
3.7.2. Cargo Engineering

3.8. Vector Manufacturing
3.8.1. Types of Vector Manufacturers
3.8.2. Viral Vector Manufacturing Processes
3.8.2.1 Vector Production
3.8.2.2. Adherent and Suspension Cultures
3.8.2.3. Unit Process Versus Multiple Parallel Processes
3.8.2.4. Cell Culture Systems for Production of Viral Vectors
3.8.2.4.1. Small / Laboratory Scale Cell Culture Systems
3.8.2.4.2. Large Scale Cell Culture Systems
3.8.2.4.2.1. Stirred-Tank Reactor Systems
3.8.2.4.2.2. Fixed Bed Reactor / Packed Bed Reactor
3.8.2.4.2.3. WAVE Bioreactor System
3.8.2.5. Serum-Containing versus Serum-Free Media

3.8.3. Bioprocessing of Viral Vectors
3.8.3.1. AAV Vector Production
3.8.3.2. Adenoviral Vector Production
3.8.3.3. Lentiviral Vector Production
3.8.3.4. γ -Retroviral Vector Production
3.8.4. Challenges Related to Vector Manufacturi

3.9. Future of Vector Manufacturing
 
4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location of Headquarters
4.2.4. Analysis by Type of Manufacturer
4.2.5. Analysis by Geographical Location of Manufacturing Facilities
4.2.6. Analysis by Scale of Production
4.2.7. Analysis by Purpose of Production
4.2.8. Analysis by Type of Vector
4.2.9. Analysis by Application Area
 
5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geographical Location of Headquarters
5.2.4. Analysis by Type of Manufacturer 
5.2.5. Analysis by Geographical Location of Manufacturing Facilities
5.2.6. Analysis by Scale of Production 
5.2.7. Analysis by Purpose of Production
5.2.8. Analysis by Application Area
 
6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE
6.1. Chapter Overview
6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Geographical Location of Manufacturing Facilities
6.2.3. Analysis by Purpose of Production
6.2.4. Analysis by Scale of Production
6.2.5. Analysis by Type of Vector
6.2.5. Analysis by Application Area
 
7. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Aldevron
7.2.1. Company Overview
7.2.2. Manufacturing Facilities
7.2.3. Manufacturing Experience
7.2.4. Recent Developments and Future Outlook

7.3. BioReliance / SAFC Commercial (Merck KGaA)
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Vector Manufacturing Technology Portfolio
7.3.4. Manufacturing Facilities
7.3.5. Recent Developments and Future Outlook

7.4. bluebird bio
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Manufacturing Facilities
7.4.4. Manufacturing Experience
7.4.5. Recent Development and Future Outlook

7.5. Brammer Bio
7.5.1. Company Overview
7.5.2. Manufacturing Facilities
7.5.3. Manufacturing Experience
7.5.4. Recent Developments and Future Outlook

7.6. FUJIFILM Diosynth Biotechnologies
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Manufacturing Facilities
7.6.4. Manufacturing Experience
7.6.5. Recent Developments and Future Outlook

7.7. MassBiologics
7.7.1. Company Overview
7.7.2. Manufacturing Facilities
7.7.3. Recent Developments and Future Outlook

7.8. Novasep
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. Manufacturing Facilities
7.8.4. Manufacturing Experience
7.8.5. Recent Developments and Future Outlook

7.9. Spark Therapeutics
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. Manufacturing Facilities
7.9.4. Vector Manufacturing Technology Portfolio
7.9.5. Manufacturing Experience
7.9.6. Recent Developments and Future Outlook

7.10. Vigene Biosciences
7.10.1. Company Overview
7.10.2. Manufacturing Facilities
7.10.3. Vector Manufacturing Technology Portfolio
7.10.4. Manufacturing Experience
7.10.5. Recent Developments and Future Outlook
 
8. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
8.1. Chapter Overview
8.2. Biovian
8.2.1. Company Overview
8.2.2. Manufacturing Facilities
8.2.3. Recent Developments and Future Outlook

8.3. Cell and Gene Therapy Catapult
8.3.1. Company Overview
8.3.2. Manufacturing Facilities
8.3.3. Recent Developments and Future Outlook

8.4. Cobra Biologics
8.4.1. Company Overview
8.4.2. Manufacturing Facilities
8.4.3. Vector Manufacturing Technology Portfolio
8.4.4. Manufacturing Experience
8.4.5. Recent Developments and Future Outlook

8.5. FinVector
8.5.1. Company Overview
8.5.2. Manufacturing Facilities
8.5.3. Vector Manufacturing Technology Portfolio
8.5.4. Manufacturing Experience
8.5.5. Recent Developments and Future Outlook

8.6. Kaneka Eurogentec
8.6.1. Company Overview
8.6.2. Manufacturing Facilities
8.6.3. Manufacturing Experience
8.6.4. Recent Developments and Future Outlook

8.7. Lonza
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Vector Manufacturing Technology Portfolio
8.7.4. Manufacturing Facilities
8.7.5. Recent Developments and Future Outlook

8.8. MolMed
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Manufacturing Facilities
8.8.4. Recent Developments and Future Outlook

8.9. Oxford BioMedica
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Manufacturing Facilities
8.9.4. Vector Manufacturing Technology Portfolio
8.9.5. Manufacturing Experience
8.9.6. Recent Developments and Future Outlook

8.10. Richter-Helm
8.10.1. Company Overview
8.10.2. Manufacturing Facilities
8.10.3. Recent Developments and Future Outlook

8.11. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
8.11.1. Company Overview
8.11.2. Financial Information
8.11.3. Manufacturing Facilities
8.11.4. Recent Developments and Future Outlook

8.12. uniQure
8.12.1. Company Overview
8.12.2. Financial Information
8.12.3. Manufacturing Facilities
8.12.4. Vector Manufacturing Technology Portfolio
8.12.5. Recent Developments and Future Outlook

8.13. VIVEbiotech
8.13.1. Company Overview
8.13.2. Vector Manufacturing Technology Portfolio
8.13.3. Manufacturing Facilities
8.13.4. Recent Developments and Future Outlook
 
9. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
9.1. Chapter Overview
9.2. Wuxi AppTec
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Manufacturing Facilities
9.2.4. Manufacturing Experience
9.2.5. Recent Developments and Future Outlook
9.3. Other Key Players
 
10. EMERGING VECTORS
10.1. Chapter Overview
10.1.1. Alphavirus Based Vectors
10.1.2. Anc80 Based Vectors
10.1.3. Bifidobacterium longum Based Vectors
10.1.4. Cytomegalovirus Based Vectors
10.1.5. Listeria monocytogenes Based Vectors
10.1.6. Minicircle DNA Based Vectors
10.1.7. Myxoma Virus Based Vectors
10.1.8. Self-Complementary Vectors
10.1.9. Sendai Virus Based Vectors
10.1.10. Sleeping Beauty Transposons
10.1.11. Vaccinia Virus and Modified Vaccinia Ankara Based Vectors
 
11. RECENT COLLABORATIONS AND PARTNERSHIPS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Vector and Gene Therapy Manufacturing: Recent Collaborations and Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Type of Vector
11.3.4. Analysis by Scale of Operation
11.3.5. Analysis by Number of Partnerships: Most Active Players
11.3.6. Regional Analysis
11.3.6.1. Most Active Players in Different Geographical Regions
11.3.6.2. Intercontinental and Intracontinental Agreements
11.4. Other Collaborations
 
12. KEY INSIGHTS
12.1. Chapter Overview
12.2. Vector and Gene Therapy Manufacturers: Analysis of Competitive Landscape by Purpose of Production, Type of Vector and Scale of Operation 
12.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size and Type of Vector
12.4. Vector and Gene Therapy Manufacturers: Prominent Geographical Hubs by Type of Organization
12.4.1. Contract Manufacturers
12.4.2. In-House Manufacturers

12.5. Vector and Gene Therapy Manufacturers: Analysis by Location of Manufacturing Facilities and Type of Vector
12.5.1. AAV Vector Manufacturers
12.5.2. Adenoviral Vector Manufacturers
12.5.3. Lentiviral Vector Manufacturers
12.5.4. Retroviral Vector Manufacturers
12.5.5. Plasmid DNA Manufacturers
 
13. VIRAL VECTOR AND PLASMID DNA COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA Based Therapies
13.3. Viral Vector and Plasmid DNA Based Therapies: Pricing Models 
13.3.1. On the Basis of Expert Opinions
13.3.2. On the Basis of Manufacturing Cost
13.3.2.1. On the Basis of Technology Used
13.3.2.2. On the Basis of Scale of Manufacturing
13.3.2.3. On the Basis of Client Type
13.3.3. Prices of Different Types of Vectors
13.4. Concluding Remarks
 
14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Installed, Global Viral Vector Manufacturing Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Location of Manufacturing Facilities

14.4. Installed, Global Plasmid DNA Manufacturing Capacity
14.4.1. Analysis by Company Size
14.4.2. Analysis by Scale of Operation
14.4.3. Analysis by Location of Manufacturing Facilities

14.5. Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity
14.6. Concluding Remarks
 
15. DEMAND ANALYSIS
15.1.  Chapter Overview
15.2.  Assumptions and Methodology

15.3. Global, Clinical Demand for Viral Vector and Plasmid DNA
15.3.1. Analysis by Type of Vector 
15.3.2. Analysis by Type of Therapy
15.3.3. Analysis by Type of Therapeutic Area
15.3.4. Analysis by Type of Geographical Location

15.4. Global, Commercial Demand for Viral Vector and Plasmid DNA
15.4.1. Analysis by Type of Vector 
15.4.2. Analysis by Type of Therapy

15.4.3. Analysis by Type of Therapeutic Area
15.4.4. Analysis by Type of Geographical Location

15.5. Demand and Supply Analysis
15.5.1. Demand and Supply Analysis (Scenario 1)
15.5.2. Demand and Supply Analysis (Scenario 2)
15.5.3. Demand and Supply Analysis (Scenario 3)
 
16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope of the Forecast
16.3. Forecast Methodology 
16.4. Input Tables and Key Assumptions
16.5. Overall Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030
16.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Type of Vector
16.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Market Attractiveness by Type of Vector
16.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application Area 
16.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Therapeutic Area 
16.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of Operation
16.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of Production
16.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography

16.6. Current and Future Market Opportunity from Commercial Products
16.6.1. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.2. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
16.6.3. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
16.6.4. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2019-2030: Distribution by Type of Vector

16.6.4.1. AAV Vectors
16.6.4.1.1. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.4.1.2. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
16.6.4.1.3. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography

16.6.4.2. Adenoviral Vectors
16.6.4.2.1. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.4.2.2. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area 
16.6.4.2.3. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography 

16.6.4.3. Lentiviral Vectors
16.6.4.3.1. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.4.3.2. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area 
16.6.4.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography 

16.6.4.4. Retroviral Vectors
16.6.4.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.4.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area 
16.6.4.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography

16.6.4.5. Plasmid DNA
16.6.4.5.1. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.4.5.2. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area 
16.6.4.5.3. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography

16.7. Current and Future Market Opportunity from Clinical Candidates 
16.7.1. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.2. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
16.7.3. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
16.7.4. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Type of Vector

16.7.4.1. AAV Vectors
16.7.4.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.4.1.2. AAV Vector Manufacturing Market for Clinical Products, 2019-2030: Distribution by Phase of Development
16.7.4.1.3. AAV Vector Manufacturing Market for Clinical Products, 2019-2030: Distribution by Geography

16.7.4.2. Adenoviral Vectors
16.7.4.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.4.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development 
16.7.4.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography 16.7.4.3. Lentiviral Vectors
16.7.4.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.4.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development 
16.7.4.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography 

16.7.4.4. Retroviral Vectors
16.7.4.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.4.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development 
16.7.4.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography 

16.7.4.5. Plasmid DNA
16.7.4.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.4.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
16.7.4.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography 

16.8. Current and Future Market Opportunity from Preclinical Candidates
16.8.1. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.2. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
16.8.3. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Animal Model Used
16.8.4. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
16.8.5. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Type of Vector

16.8.5.1. AAV Vectors
16.8.5.1.1. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.5.1.2. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.5.1.3. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography

16.8.5.2. Adenoviral Vectors
16.8.5.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.5.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.5.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography

16.8.5.3. Lentiviral Vectors
16.8.5.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area 
16.8.5.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.5.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography 

16.8.5.4. Retroviral Vectors
16.8.5.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.5.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.5.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography

16.8.5.5. Plasmid DNA
16.8.5.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.5.5.2. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.5.5.3. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography 

16.9 Current and Future Market opportunity from Vector-Based Vaccines
16.9.1. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Type of Vector
16.9.2. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Scale of Operation
16.9.3. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Therapeutic Indication
16.9.4. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Geography

17. KEY DRIVERS AND CHALLENGES
17.1. Chapter Overview
17.2. Viral Vector and Plasmid DNA Manufacturing Market: Drivers and Challenges
17.2.1. AAV Vectors
17.2.2. Adenoviral Vectors
17.2.3. Lentiviral Vectors
17.2.4. Retroviral Vectors
17.2.5. Plasmid DNA
17.3. Concluding Remarks
 
18. SURVEY ANALYSIS
18.1. Chapter Overview
18.2. Seniority Level of Respondents
18.3. Type of Vector
18.4. Scale of Production
18.5. Vector Stabilization Technology
18.6. In-house / Contract Operations
 
19. CONCLUDING REMARKS
 
20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Batavia Biosciences
20.2.1. Company Snapshot 
20.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and President

20.3. CEVEC Pharmaceuticals
20.3.1. Company Snapshot 
20.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer

20.4. Vigene Biosciences
20.4.1. Company Snapshot 
20.4.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer

20.5. Clean Cells
20.5.1. Company Snapshot 
20.5.2. Interview Transcript: Laurent Ciavatti, Business Development Manager, Olivier Boisteau, Co-Founder / President and Xavier Leclerc, Head of Gene Therapy

20.6. Amsterdam BioTherapeutics Unit (AmBTU)
20.6.1. Company Snapshot 
20.6.2. Interview Transcript: Joost van den Berg, Director

20.7. MGH Viral Vector Development Facility, Massachusetts General Hospital
20.7.1. Company Snapshot 
20.7.2. Interview Transcript: Bakhos A Tannous, Director

20.8. CJ PARTNERS
20.8.1. Company Snapshot 
20.8.2. Interview Transcript: Interview Transcript, Colin Lee Novick, Managing Director

20.9. Delphi Genetics
20.9.1. Company Snapshot 
20.9.2. Interview Transcript: Cedric Szpirer, Executive & Scientific Director

20.10. ACGT
20.10.1. Company Snapshot 
20.10.2. Interview Transcript: Semyon Rubinchik, Scientific Director

20.11. Translational Vector Core, University of Nantes
20.11.1. Company Snapshot 
20.11.2. Interview Transcript: Eduard Ayuso, DVM, PhD, Scientific Director

20.12. Novasep
20.12.1. Company Snapshot 
20.12.2. Interview Transcript: Alain Lamproye, President of Biopharma Business Unit

20.13. Richter-Helm
20.13.1. Company Snapshot 
20.13.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development

20.14. Waisman Biomanufacturing
20.14.1. Company Snapshot 
20.14.2. Interview Transcript: Brian M Dattilo, Business Development Manager

20.15. Plasmid Factory
20.15.1. Company Snapshot 
20.15.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager

20.16. GEG Tech
20.16.1. Company Snapshot 
20.16.2. Interview Transcript: Nicolas Grandchamp, R&D Leader

20.16. EFS-West Biotherapy
20.16.1. Company Snapshot 
20.16.2. Interview Transcript: Beatrice Araud, ATMP Key Account Manager

21. APPENDIX I: TABULATED DATA
 
22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Gene Transfer: Viral and Non-Viral Methods
Figure 3.2 Vector Manufacturing: Types of Manufacturers
Figure 3.3 Viral Vectors: Manufacturing Process
Figure 4.1  Viral Vector and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
Figure 4.2  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continents)
Figure 4.4  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries)
Figure 4.5  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 4.6  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continents)
Figure 4.7  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Countries)
Figure 4.8  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Figure 4.9  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Figure 4.10  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector
Figure 4.11  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 5.1  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
Figure 5.2  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 5.3  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continents)
Figure 5.4  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries)
Figure 5.5  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 5.6  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continents)
Figure 5.7  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Countries)
Figure 5.8  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Figure 5.9  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Figure 5.10  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 6.1  Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Figure 6.2  Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Geographical Location of Manufacturing Facilities (Continents)
Figure 6.3  Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Geographical Location of Manufacturing Facilities (Countries)
Figure 6.4  Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Figure 6.5  Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Scale of Production
Figure 6.6  Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Type of Vector
Figure 6.7  Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Application Area
Figure 7.1  Merck KGaA: Annual Revenues, 2014-H1 2019 (EUR Billion)
Figure 7.2  Merck KGaA: Annual Revenues by Business Sector, 2018 (EUR Billion)
Figure 7.3  H.A.V.E.: AAV Vector Manufacturing Technology
Figure 7.4  bluebird bio: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 7.5  bluebird bio Viral Vectors: Stages of Manufacturing Process
Figure 7.6  FUJIFILM Holdings: Annual Revenues, 2013-H1 2019 (JPY Billion)
Figure 7.7  FUJIFILM Holdings: Revenues by Business Divisions, 2018 (JPY Billion)
Figure 7.8  Novasep: Annual Revenues, 2013-2017 (EUR Million)
Figure 7.9  Novasep: Viral Vector Manufacturing Process
Figure 7.10  Spark Therapeutics: Annual Revenues, 2014-2018 (USD Million)
Figure 8.1  Lonza: Annual Revenues, 2014- H1 2019 (CHF Million)
Figure 8.2  MolMed: Annual Revenues, 2013-H1 2019 (EUR Million)
Figure 8.3  Oxford BioMedica: Annual Revenues, 2014-H1 2019 (GBP Million)
Figure 8.4  Sanofi: Annual Revenues, 2014-H1 2019 (EUR Billion)
Figure 8.5  uniQure: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 9.1  Wuxi AppTec: Annual Revenues, 2017-H1 2019 (RMB Million)
Figure 11.1  Vector and Gene Therapy Partnerships: Cumulative Year-wise Trend (2015–2019)
Figure 11.2 Vector and Gene Therapy Partnerships: Distribution by Type of Partnership
Figure 11.3 Vector and Gene Therapy Partnerships: Distribution by Type and Year of Partnership
Figure 11.4 Vector and Gene Therapy Partnerships: Distribution by Type of Vector
Figure 11.5 Vector and Gene Therapy Partnerships: Distribution by Scale of Operation
Figure 11.6  Vector and Gene Therapy Partnerships: Most Active Players
Figure 11.7  Vector and Gene Therapy Partnerships: Regional Distribution and Most Active Players
Figure 11.8  Vector and Gene Therapy Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Figure 12.1  Vector and Gene Therapy Manufacturers: Competitive Landscape by Purpose of Production, Type of Vector and Scale of Operation
Figure 12.2  Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of Vector
Figure 12.3  Vector and Gene Therapy Contract Manufacturers: Prominent Geographical Hubs
Figure 12.4  Vector and Gene Therapy In-House Manufacturers: Prominent Geographical Hubs
Figure 12.5  AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 12.6  Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 12.7  Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 12.8  Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 12.9  Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 13.1  Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 14.1  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 14.2  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 14.3  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Figure 14.4  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity
Figure 14.5  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Scale of Operation
Figure 14.6  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
Figure 14.7  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Figure 14.8  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity
Figure 14.9  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation
Figure 14.10  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities
Figure 14.11  Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector
Figure 14.12  Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
Figure 15.1. Global Clinical Demand for Viral Vector and Plasmid DNA, 2019-2030 (Thousand Patients)
Figure 15.2.  Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Figure 15.3.  Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 15.4.  Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 15.5.  Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 15.6.  Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients) 
Figure 15.7.  Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Figure 15.8.  Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 15.9.  Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 15.10.  Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 15.11  Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2019-2030
Figure 15.12  Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2019-2030
Figure 15.13  Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2019-2030
Figure 16.1  Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030 (USD Million)
Figure 16.2  Viral Vector and Plasmid DNA Manufacturing, 2019-2030: Distribution by Type of Vector (USD Million)
Figure 16.3  Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Market Attractiveness Analysis by Type of Vector
Figure 16.4  Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.5  Viral Vector and Plasmid DNA Manufacturing Market, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
Figure 16.6 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 16.7 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of Production (USD Million)
Figure 16.8  Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
Figure 16.9  Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.10  Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products in 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
Figure 16.11  Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products in 2020, 2025 and 2030: Distribution by Geography (USD Million)
Figure 16.12  Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, 2020, 2025 and 2030: Distribution by Type of Vector (USD Million)
Figure 16.13  AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.14  AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million) 
Figure 16.15  AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million) 
Figure 16.16  Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.17  Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.18  Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Figure 16.19  Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.20  Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.21  Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Figure 16.22  Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.23  Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.24  Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Figure 16.25  Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.26  Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.27  Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Figure 16.28  Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.29  Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
Figure 16.30  Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates in 2020, 2025 and 2030: Distribution by Geography (USD Million)
Figure 16.31  Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Type of Vector (USD Million)
Figure 16.32  AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.33  AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
Figure 16.34  AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.35  Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.36  Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
Figure 16.37  Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.38  Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.39  Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
Figure 16.40  Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.41  Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.42  Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
Figure 16.43  Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.44  Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.45  Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development (USD Million)
Figure 16.46  Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.47  Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million) 
Figure 16.48  Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million) 
Figure 16.49  Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Animal Model Used (USD Million)
Figure 16.50  Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2020, 2025 and 2030: Distribution by Geography (USD Million)
Figure 16.51  Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Vector (USD Million)
Figure 16.52 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.53 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Figure 16.54 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.55 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.56 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Figure 16.57 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.58 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.59 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Figure 16.60 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.61 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.62 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Figure 16.63 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.64 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
Figure 16.65 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Figure 16.66 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Figure 16.67  Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Type of Vector (USD Million) 
Figure 16.68  Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 16.69  Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Therapeutic Indication (USD Million)
Figure 16.70  Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2019-2030: Distribution by Geography (USD Million)
Figure 17.1  AAV Vectors: Drivers and Challenges
Figure 17.2  Adenoviral Vectors: Drivers and Challenges
Figure 17.3  Lentiviral Vectors: Drivers and Challenges
Figure 17.4  Retroviral Vectors: Drivers and Challenges
Figure 17.5  Plasmid DNA: Drivers and Challenges
Figure 18.1  Survey Analysis: Distribution by Type of Organization
Figure 18.2  Survey Analysis: Distribution by Geographical Location of Organization
Figure 18.3  Survey Analysis: Distribution by Seniority Level of Respondents
Figure 18.4  Survey Analysis: Distribution by Type of Vector
Figure 18.5  Survey Analysis: Distribution by Scale of Production
Figure 18.6  Survey Analysis: Vector Stabilization Technology
Figure 18.7  Survey Analysis: Distribution by Purpose of Production (In-house Production versus Contract Services)
Figure 19.1  Viral Vectors and Plasmid DNA Market: Distribution by Vector Type, 2020, 2025, 2030 (USD Million)

List of Tables

Table 3.1     Viral Vectors: Key Features
Table 3.2    Small Scale Cell Culture Systems
Table 4.1     Viral Vector and Gene Therapy Manufacturers: List of Industry Players 
Table 4.2     Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Manufacturing Facilities, Scale of Production and Purpose of Production
Table 4.3     Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Types of Viral Vectors
Table 4.4.    Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 5.1     Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 5.2     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Manufacturing Facilities, Scale of Production and Purpose of Production 
Table 5.3    Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 6.1     Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 6.2     Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Production
Table 6.3     Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vectors
Table 6.4    Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 7.1     Vector and Gene Therapy Production in North America: List of Profiled Companies
Table 7.2     Aldevron Plasmid DNA: QC Assays
Table 7.3.    Aldevron: Recent Developments and Future Outlook
Table 7.4.    BioReliance / SAFC Commercial (Merck KGaA): Recent Developments and Future Outlook
Table 7.5    bluebird bio: Recent Developments and Future Outlook
Table 7.6    Brammer Bio: Recent Developments and Future Outlook
Table 7.7    FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 7.8    MassBiologics: Recent Developments and Future Outlook
Table 7.9     Novasep Viral Vectors: Manufacturing Experience
Table 7.10    Novasep: Recent Developments Future Outlook
Table 7.11    Spark Therapeutics: Recent Developments and Future Outlook
Table 7.12    Vigene Biosciences: Recent Developments and Future Outlook
Table 8.1     Vector and Gene Therapy Production in Europe: List of Players Profiled
Table 8.2    Biovian: Recent Developments and Future Outlook
Table 8.3    Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 8.4    Cobra Biologics: Recent Developments and Future Outlook
Table 8.5    Kaneka Eurogentec: Recent Developments and Future Outlook
Table 8.6    Lonza: Recent Developments and Future Outlook
Table 8.7    MolMed: Recent Developments and Future Outlook
Table 8.8    Oxford BioMedica: Recent Developments and Future Outlook
Table 8.9    Sanofi: Recent Developments and Future Outlook
Table 8.10    uniQure: Recent Developments and Future Outlook
Table 8.11    VIVEbiotech: Recent Developments and Future Outlook
Table 9.1    Wuxi AppTec: Recent Developments and Future Outlook
Table 9.2     List of Key Players based in Asia Pacific
Table 11.1    Vector and Gene Therapy Manufacturing: List of Partnerships
Table 11.2    Vector and Gene Therapy Manufacturing Partnerships: Most Active Players
Table 11.3    Vector and Gene Therapy Manufacturing: List of Other Partnerships
Table 13.1    Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 13.2     Viral Vector and Plasmid DNA: Prices of Vectors
Table 14.1     Installed, Global Viral Vector Manufacturing Capacity: Sample Data Set
Table 14.2     Installed, Global Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 14.3     Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 14.4     Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 15.1.     Global Viral Vectors Manufacturing Annual Demand, 2019-2030 (1020 vg)
Table 15.2     Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2019-2030 (1020 vg)
Table 15.3     Global Viral Vector Manufacturing: Annual Supply (Scenario 2), 2019-2030 (1020 vg)
Table 15.4     Global Viral Vector Manufacturing: Annual Supply (Scenario 3), 2019-2030 (1020 vg)
Table 16.1     Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 16.2     Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 16.3     Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2019-2030
Table 16.4     Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2019-2030
Table 16.5     Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 18.1     Survey Response: Overview of the Participating Companies / Organizations
Table 18.2     Survey Response: Seniority Level of Respondents
Table 18.3     Survey Response: Type of Vector
Table 18.4     Survey Response: Scale of Production
Table 18.5     Survey Response: Vector Stabilization Technology
Table 18.6     Survey Response: Purpose of Production (In-house Production versus Contract Services)    
Table 20.1     Batavia Biosciences: Key Highlights
Table 20.2     CEVEC Pharmaceuticals: Key Highlights
Table 20.3     Clean Cells: Key Highlights
Table 20.4     Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 20.5     MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 20.6     CJ PARTNERS Key Highlights
Table 20.7     Delphi Genetics: Key Highlights
Table 20.8     ACGT: Key Highlights
Table 20.9     Translational Vector Core, University of Nantes: Key Highlights
Table 20.10     Waisman Biomanufacturing: Key Highlights
Table 20.11     PlasmidFactory: Key Highlights
Table 20.12     GEG Tech: Key Highlights
Table 20.13     EFS-West Biotherapy: Key Highlights
Table 21.1     Viral Vector and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
Table 21.2     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 21.3     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continents)
Table 21.4     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries)
Table 21.5     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 21.6     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continents)
Table 21.7     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Countries)
Table 21.8     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 21.9     Viral Vector Manufacturers and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Table 21.10     Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector
Table 21.11    Viral Vector and Gene Therapy Manufacturers (Industry Players):  Distribution by Application Area
Table 21.12     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
Table 21.13    Plasmid DNA and Gene Therapy Manufacturers (Industry Players):  Distribution by Company Size
Table 21.14    Plasmid DNA and Gene Therapy Manufacturers (Industry Players):  Distribution by Geographical Location of Headquarters (Continents)
Table 21.15    Plasmid DNA and Gene Therapy Manufacturers (Industry Players):  Distribution by Geographical Location of Headquarters (Countries)
Table 21.16     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 21.17     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continents)
Table 21.18     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Countries)
Table 21.19     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 21.20     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Table 21.21    Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 21.22    Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Table 21.23    Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Geographical Location of Manufacturing Facilities (Continents)
Table 21.24    Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Geographical Location of Manufacturing Facilities (Countries)
Table 21.25    Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Table 21.26    Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Scale of Production
Table 21.27    Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Type of Vector
Table 21.28    Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Application Area
Table 21.29     Merck KGaA: Annual Revenues, 2014-H1 2019 (EUR Billion)
Table 21.30     Merck KGaA: Annual Revenues by Business Sector, 2018 (EUR Billion)
Table 21.31     bluebird bio: Annual Revenues, 2014-H1 2019 (USD Million)
Table 21.32     FUJIFILM Holdings: Annual Revenues, 2013-H1 2019 (JPY Billion)
Table 21.33     FUJIFILM Holdings: Revenues by Business Divisions, FY 2018 (JPY Billion)
Table 21.34     Novasep: Revenues, 2013-2017 (EUR Million)
Table 21.35     Spark Therapeutics: Annual Revenues, 2014-2018 (USD Million)
Table 21.36     Lonza: Annual Revenues, 2014-H1 2019 (CHF Million)
Table 21.37     MolMed: Annual Revenues, 2013-H1 2019 (EUR Million)
Table 21.38     Oxford BioMedica: Annual Revenues, 2014-H1 2019 (GBP Million)
Table 21.39     Sanofi: Annual Revenues, 2014-H1 2019 (EUR Billion)
Table 21.40     uniQure: Annual Revenues, 2014-H1 2019 (USD Million)
Table 21.41     Wuxi AppTec: Annual Revenues, 2017-H1 2019 (RMB Million)
Table 21.42     Vector and Gene Therapy Partnerships: Cumulative Year-wise Trend (2015- 2019)
Table 21.43     Vector and Gene Therapy Partnerships: Distribution by Type of Partnership
Table 21.44    Vector and Gene Therapy Partnerships: Distribution by Type and Year of Partnership
Table 21.45     Vector and Gene Therapy Partnerships: Distribution by Type of Vector
Table 21.46     Vector and Gene Therapy Partnerships: Distribution by Scale of Operation
Table 21.47     Vector and Gene Therapy Partnerships: Most Active Players
Table 21.48     Vector and Gene Therapy Partnerships: Regional Distribution and Most Active Players
Table 21.49     Vector and Gene Therapy Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 21.50     Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 21.51     Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 21.52     Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 21.53     Installed, Global Viral Vector Manufacturing Capacity: Distribution by Scale of Operation
Table 21.54     Installed, Global Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
Table 21.55     Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 21.56     Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation
Table 21.57     Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
Table 21.58     Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector
Table 21.59    Global Clinical Demand for Viral Vector and Plasmid DNA, 2019-2030 (Thousand Patients)
Table 21.60    Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 21.61    Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 21.62     Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 21.63    Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 21.64    Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients) 
Table 21.65    Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 21.66    Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 21.67    Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 21.68    Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 21.69     Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030 (USD Million)
Table 21.70     Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Vector (USD Million)
Table 21.71     Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.72     Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
Table 21.73     Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Scale of Operation (USD Million)
Table 21.74    Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Purpose of Production (USD Million)
Table 21.75     Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.76    Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.77    Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
Table 21.78    Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Geography (USD Million)
Table 21.79    Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Type of Vector (USD Million)
Table 21.80     AAV Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.81     AAV Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.82     AAV Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.83     Adenoviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.84     Adenoviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.85     Adenoviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.86     Lentiviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.87     Lentiviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.88     Lentiviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.89     Retroviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.90     Retroviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.91     Retroviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.92     Plasmid DNA Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.93     Plasmid DNA Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.94     Plasmid DNA Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.95    Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.96    Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Phase of Development (USD Million)
Table 21.97    Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Geography (USD Million)
Table 21.98    Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Vector (USD Million)
Table 3.1  Viral Vectors: Key Features
Table 3.2 Small Scale Cell Culture Systems
Table 4.1  Viral Vector and Gene Therapy Manufacturers: List of Industry Players 
Table 4.2  Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Manufacturing Facilities, Scale of Production and Purpose of Production
Table 4.3  Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Types of Viral Vectors
Table 4.4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 5.1  Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 5.2  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Manufacturing Facilities, Scale of Production and Purpose of Production 
Table 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 6.1  Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 6.2  Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Production
Table 6.3  Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vectors
Table 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 7.1  Vector and Gene Therapy Production in North America: List of Profiled Companies
Table 7.2  Aldevron Plasmid DNA: QC Assays
Table 7.3. Aldevron: Recent Developments and Future Outlook
Table 7.4. BioReliance / SAFC Commercial (Merck KGaA): Recent Developments and Future Outlook
Table 7.5 bluebird bio: Recent Developments and Future Outlook
Table 7.6 Brammer Bio: Recent Developments and Future Outlook
Table 7.7 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 7.8 MassBiologics: Recent Developments and Future Outlook
Table 7.9  Novasep Viral Vectors: Manufacturing Experience
Table 7.10 Novasep: Recent Developments Future Outlook
Table 7.11 Spark Therapeutics: Recent Developments and Future Outlook
Table 7.12 Vigene Biosciences: Recent Developments and Future Outlook
Table 8.1  Vector and Gene Therapy Production in Europe: List of Players Profiled
Table 8.2 Biovian: Recent Developments and Future Outlook
Table 8.3 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 8.4 Cobra Biologics: Recent Developments and Future Outlook
Table 8.5 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 8.6 Lonza: Recent Developments and Future Outlook
Table 8.7 MolMed: Recent Developments and Future Outlook
Table 8.8 Oxford BioMedica: Recent Developments and Future Outlook
Table 8.9 Sanofi: Recent Developments and Future Outlook
Table 8.10 uniQure: Recent Developments and Future Outlook
Table 8.11 VIVEbiotech: Recent Developments and Future Outlook
Table 9.1 Wuxi AppTec: Recent Developments and Future Outlook
Table 9.2  List of Key Players based in Asia Pacific
Table 11.1 Vector and Gene Therapy Manufacturing: List of Partnerships
Table 11.2 Vector and Gene Therapy Manufacturing Partnerships: Most Active Players
Table 11.3 Vector and Gene Therapy Manufacturing: List of Other Partnerships
Table 13.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 13.2  Viral Vector and Plasmid DNA: Prices of Vectors
Table 14.1  Installed, Global Viral Vector Manufacturing Capacity: Sample Data Set
Table 14.2  Installed, Global Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 14.3  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 14.4  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 15.1.  Global Viral Vectors Manufacturing Annual Demand, 2019-2030 (1020 vg)
Table 15.2  Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2019-2030 (1020 vg)
Table 15.3  Global Viral Vector Manufacturing: Annual Supply (Scenario 2), 2019-2030 (1020 vg)
Table 15.4  Global Viral Vector Manufacturing: Annual Supply (Scenario 3), 2019-2030 (1020 vg)
Table 16.1  Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 16.2  Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 16.3  Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2019-2030
Table 16.4  Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2019-2030
Table 16.5  Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 18.1  Survey Response: Overview of the Participating Companies / Organizations
Table 18.2  Survey Response: Seniority Level of Respondents
Table 18.3  Survey Response: Type of Vector
Table 18.4  Survey Response: Scale of Production
Table 18.5  Survey Response: Vector Stabilization Technology
Table 18.6  Survey Response: Purpose of Production (In-house Production versus Contract Services)
Table 20.1  Batavia Biosciences: Key Highlights
Table 20.2  CEVEC Pharmaceuticals: Key Highlights
Table 20.3  Clean Cells: Key Highlights
Table 20.4  Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 20.5  MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 20.6  CJ PARTNERS Key Highlights
Table 20.7  Delphi Genetics: Key Highlights
Table 20.8  ACGT: Key Highlights
Table 20.9  Translational Vector Core, University of Nantes: Key Highlights
Table 20.10  Waisman Biomanufacturing: Key Highlights
Table 20.11  PlasmidFactory: Key Highlights
Table 20.12  GEG Tech: Key Highlights
Table 20.13  EFS-West Biotherapy: Key Highlights
Table 21.1  Viral Vector and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
Table 21.2  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 21.3  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continents)
Table 21.4  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Countries)
Table 21.5  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 21.6  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continents)
Table 21.7  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Countries)
Table 21.8  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 21.9  Viral Vector Manufacturers and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Table 21.10  Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector
Table 21.11 Viral Vector and Gene Therapy Manufacturers (Industry Players):  Distribution by Application Area
Table 21.12  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Establishment
Table 21.13 Plasmid DNA and Gene Therapy Manufacturers (Industry Players):  Distribution by Company Size
Table 21.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players):  Distribution by Geographical Location of Headquarters (Continents)
Table 21.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players):  Distribution by Geographical Location of Headquarters (Countries)
Table 21.16  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 21.17  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continents)
Table 21.18  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Countries)
Table 21.19  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Production
Table 21.20  Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Table 21.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 21.22 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Table 21.23 Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Geographical Location of Manufacturing Facilities (Continents)
Table 21.24 Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Geographical Location of Manufacturing Facilities (Countries)
Table 21.25 Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Purpose of Production (In-house Production versus Contract Manufacturing Services)
Table 21.26 Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Scale of Production
Table 21.27 Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Type of Vector
Table 21.28 Vector and Gene Therapy Manufacturers (Non-Industry Players):  Distribution by Application Area
Table 21.29  Merck KGaA: Annual Revenues, 2014-H1 2019 (EUR Billion)
Table 21.30  Merck KGaA: Annual Revenues by Business Sector, 2018 (EUR Billion)
Table 21.31  bluebird bio: Annual Revenues, 2014-H1 2019 (USD Million)
Table 21.32  FUJIFILM Holdings: Annual Revenues, 2013-H1 2019 (JPY Billion)
Table 21.33  FUJIFILM Holdings: Revenues by Business Divisions, FY 2018 (JPY Billion)
Table 21.34  Novasep: Revenues, 2013-2017 (EUR Million)
Table 21.35  Spark Therapeutics: Annual Revenues, 2014-2018 (USD Million)
Table 21.36  Lonza: Annual Revenues, 2014-H1 2019 (CHF Million)
Table 21.37  MolMed: Annual Revenues, 2013-H1 2019 (EUR Million)
Table 21.38  Oxford BioMedica: Annual Revenues, 2014-H1 2019 (GBP Million)
Table 21.39  Sanofi: Annual Revenues, 2014-H1 2019 (EUR Billion)
Table 21.40  uniQure: Annual Revenues, 2014-H1 2019 (USD Million)
Table 21.41  Wuxi AppTec: Annual Revenues, 2017-H1 2019 (RMB Million)
Table 21.42  Vector and Gene Therapy Partnerships: Cumulative Year-wise Trend (2015- 2019)
Table 21.43  Vector and Gene Therapy Partnerships: Distribution by Type of Partnership
Table 21.44 Vector and Gene Therapy Partnerships: Distribution by Type and Year of Partnership
Table 21.45  Vector and Gene Therapy Partnerships: Distribution by Type of Vector
Table 21.46  Vector and Gene Therapy Partnerships: Distribution by Scale of Operation
Table 21.47  Vector and Gene Therapy Partnerships: Most Active Players
Table 21.48  Vector and Gene Therapy Partnerships: Regional Distribution and Most Active Players
Table 21.49  Vector and Gene Therapy Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 21.50  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 21.51  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 21.52  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 21.53  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Scale of Operation
Table 21.54  Installed, Global Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
Table 21.55  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 21.56  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation
Table 21.57  Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Geographical Location of Manufacturing Facilities
Table 21.58  Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector
Table 21.59 Global Clinical Demand for Viral Vector and Plasmid DNA, 2019-2030 (Thousand Patients)
Table 21.60 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 21.61 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 21.62  Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 21.63 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 21.64 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients) 
Table 21.65 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector (Thousand Patients)
Table 21.66 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 21.67 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 21.68 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 21.69  Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030 (USD Million)
Table 21.70  Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Vector (USD Million)
Table 21.71  Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.72  Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
Table 21.73  Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Scale of Operation (USD Million)
Table 21.74 Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Purpose of Production (USD Million)
Table 21.75  Viral Vector and Plasmid DNA Manufacturing Market, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.76 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.77 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million)
Table 21.78 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Geography (USD Million)
Table 21.79 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Type of Vector (USD Million)
Table 21.80  AAV Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.81  AAV Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.82  AAV Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.83  Adenoviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.84  Adenoviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.85  Adenoviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.86  Lentiviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.87  Lentiviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.88  Lentiviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.89  Retroviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.90  Retroviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.91  Retroviral Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.92  Plasmid DNA Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.93  Plasmid DNA Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Area (USD Million)
Table 21.94  Plasmid DNA Vectors Manufacturing Market for Commercial Products, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.95 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.96 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Phase of Development (USD Million)
Table 21.97 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Geography (USD Million)
Table 21.98 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Vector (USD Million)
Table 21.99  AAV Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.100  AAV Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Phase of Development (USD Million)
Table 21.101  AAV Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.102  Adenoviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.103  Adenoviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Phase of Development (USD Million)
Table 21.104  Adenoviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.105  Lentiviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.106  Lentiviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Phase of Development (USD Million)
Table 21.107  Lentiviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.108  Retroviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.109  Retroviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Phase of Development (USD Million)
Table 21.110  Retroviral Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.111  Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.112  Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Phase of Development (USD Million)
Table 21.113  Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.114 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million) 
Table 21.115 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Therapeutic Area (USD Million) 
Table 21.116 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Animal Model Used (USD Million)
Table 21.117 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030: Distribution by Geography (USD Million)
Table 21.118 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Vector (USD Million)
Table 21.119 AAV Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.120 AAV Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Table 21.121 AAV Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.122 Adenoviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.123 Adenoviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Table 21.124 Adenoviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.125 Lentiviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.126 Lentiviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Table 21.127 Lentiviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.128 Retroviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.129 Retroviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Table 21.130 Retroviral Vector Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.131 Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Application Area (USD Million)
Table 21.132 Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Animal Model Used (USD Million)
Table 21.133 Plasmid DNA Manufacturing Market for Preclinical Candidates, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.134 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Type of Vector (USD Million) 
Table 21.135 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Scale of Operation (USD Million)
Table 21.136 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Therapeutic Indication (USD Million)
Table 21.137 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines, Conservative, Base and Optimistic Scenario, 2019-2030: Distribution by Geography (USD Million)
Table 21.138  Survey Analysis: Distribution by Type of Organization
Table 21.120  Survey Analysis: Distribution by Geographical Location of Organization
Table 21.121 Survey Analysis: Distribution by Seniority Level of Respondents
Table 21.122 Survey Analysis: Distribution by Type of Vector
Table 21.123  Survey Analysis: Distribution by Scale of Production
Table 21.124  Survey Analysis: Vector Stabilization Technology
Table 21.125  Survey Analysis: Distribution by Purpose of Production (In-house Production versus Contract Services)

List of Companies

The following companies and organizations have been mentioned in the report.

  1. 4D Molecular Therapeutics
  2. AbbVie
  3. Abeona Therapeutics
  4. Accinov
  5. Acucela
  6. Adaptimmune Therapeutics
  7. Addgene
  8. Aduro Biotech 
  9. Advanced BioScience Laboratories (ABL)
  10. Advanced Biotherapeutics Consulting 
  11. Advaxis
  12. ADVENT
  13. Adverum Biotechnologies (previously known as Avalanche Biotechnologies)
  14. Agenzia Italiana del Farmaco
  15. Agilent Technologies
  16. Agilis Biotherapeutics 
  17. Ajinomoto Althea
  18. Aldevron
  19. Allele Biotechnology
  20. Alma Bio Therapeutics
  21. AlphaVax
  22. Althea Technologies 
  23. American Gene Technologies
  24. Amgen
  25. Amicus Therapeutics
  26. Ampersand Capital Partners
  27. AMSBIO
  28. Amsterdam BioTherapeutics Unit (AmBTU) 
  29. Amsterdam Molecular Therapeutics 
  30. Anaeropharma Science
  31. Anemocyte
  32. Annapurna Therapeutics
  33. apceth Biopharma
  34. Applied Biological Materials (ABM) 
  35. Applied Genetic Technologies (AGTC)
  36. Applied Viromics
  37. ARCO Design/Build 
  38. Areta International
  39. Asklepios BioPharmaceutical
  40. Atlantic Bio GMP 
  41. ATVIO Biotech
  42. Audentes Therapeutics
  43. Autolus
  44. Avecia Biologics 
  45. AveXis
  46. Avista Capital Partners 
  47. AVROBIO
  48. Axovant Gene Therapies
  49. Axovant Sciences 
  50. Bamboo Therapeutics 
  51. Batavia Biosciences
  52. Bavarian Nordic
  53. Baxter
  54. BCM Families Foundation
  55. Beckman Research Institute
  56. Belfer Gene Therapy Core Facility, Cornell University
  57. Benitec Biopharma
  58. BIA Separations
  59. BioCancell
  60. Bio-Ess Laboratories 
  61. Biogen 
  62. BioMarin Pharmaceuticals
  63. Biomay
  64. Biomiga 
  65. Bionic Sight
  66. BioNTech Innovative Manufacturing Service (previously known as Eufects)
  67. BioReliance
  68. Biotec Services International
  69. Biotechnology Department of San Raffaele
  70. Biotherapeutics Development Unit, Cancer Research UK 
  71. Biotherapies Institute
  72. Biotie Therapies 
  73. Bioverativ
  74. BioVex
  75. Biovian
  76. Blue Sky BioServices
  77. Bluebird Bio (previously known as Genetix Pharmaceuticals)
  78. B-MoGen Biotechnologies
  79. Boehringer Ingelheim BioXcellence™ 
  80. Boston Children’s Hospital
  81. Brammer Bio (now a part of Thermo Fisher Scientific)
  82. Brazilian Biosciences National Laboratory (LNBio)
  83. BRC Clinical Research Facility and Cell Therapy Unit, King's College London
  84. Brewin Dolphin
  85. Brickell Biotech 
  86. Bristol-Myers Squibb (BMS)
  87. Brookside Capital
  88. California Institute for Regenerative Medicine 
  89. California Institute of Technology
  90. Calimmune
  91. Cancer Research UK 
  92. Capsugel
  93. Cardiogen Sciences
  94. Carnegie Institution for Science
  95. Casey Eye Institute (CEI) and the Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University (OHSU)
  96. Catalent Biologics
  97. Celgene
  98. Cell and Gene Therapy Catapult
  99. Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  100. Celladon
  101. Cellectis
  102. CellforCure
  103. Cellular Biomedicine Group
  104. Celonic
  105. Center for Biomedicine & Genetics, City of Hope
  106. Center for Cell & Gene Therapy, Baylor College of Medicine
  107. Center for Cell and Gene Processing, Takara Bio
  108. Centre for Cell and Vector Production, Centre for Commercialization of Regenerative Medicine
  109. CEVEC Pharmaceuticals
  110. Chiesi Farmaceutici
  111. Children’s Hospital of Philadelphia 
  112. Children's GMP, St. Jude Children's Research Hospital
  113. Children's Hospital of Philadelphia
  114. Choroideremia Research Foundation (CRF)
  115. CIEMAT
  116. Cincinnati Children's Hospital Medical Center
  117. Clean Cells
  118. Clinical Biotechnology Centre, NHS Blood and Transplant
  119. Clinical Vector Production Core, University of Pittsburgh
  120. Cobra Biologics
  121. Columbus Venture Partners
  122. CombiGene
  123. Core Facility for Therapeutic Vectors, Institute of Medical Science Research Hospital
  124. Corning
  125. Cranfield University
  126. Creative Biogene
  127. Creative Biolabs
  128. Creed Commercial Development
  129. CureCell
  130. CureLab Oncology 
  131. Cytovance Biologics
  132. Deerfield Management 
  133. Delphi Genetics
  134. Department of Neuroscience, University of Minnesota
  135. Desktop Genetics
  136. Division of Human Gene Therapy, Stanford University
  137. DNAtrix
  138. Editas Medicine
  139. Elixirgen Scientific
  140. Emergent BioSolutions
  141. Epeius Biotechnologies
  142. EQT VIII Fund
  143. EUFETS 
  144. Eurofins Genomics
  145. Eurofins Scientific
  146. European Society of Gene and Cell Therapy
  147. ExcellGene
  148. Finnish Bioindustries 
  149. FinVector (previously known as Ark Therapeutics)
  150. Fisher BioServices
  151. Five Prime Therapeutics
  152. FKD Therapies
  153. Flash Therapeutics
  154. Florida Biologix
  155. Fondazione Telethon 
  156. Foundation Fighting Blindness
  157. Fraunhofer Institute for Toxicology and Experimental Medicine
  158. Freeline Therapeutics
  159. FUJIFILM Diosynth Biotechnologies
  160. GE Healthcare
  161. Gedeon Richter 
  162. GEG Tech
  163. Genable Technologies
  164. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  165. Gene Editing and Viral Vector Core, City of Hope
  166. Gene Medicine Japan
  167. Gene Silencing and Expression Facility, Robinson Research Institute, University of      Adelaide
  168. Gene Therapy Clinical Vector Production Core, University of Pittsburgh
  169. Gene Therapy Research Institute
  170. Gene Transfer Vector Core, Grousbeck Gene Therapy Center
  171. Gene Transfer Vector Core, Schepens Eye Research Institute
  172. Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies
  173. GeneCure Biotechnologies
  174. GeneDetect
  175. GeneImmune Biotechnology
  176. Genenta Science 
  177. Genethon
  178. GENEWIZ
  179. Genezen Laboratories 
  180. GenIbet Biopharmaceuticals
  181. Genprex
  182. GenScript
  183. GenVec 
  184. GeoVax Labs
  185. Germfree
  186. GIGA Institute, Liege Universite
  187. Gilead Sciences 
  188. GlaxoSmithKline
  189. Green Cross LabCell
  190. GSEx, The Robinson Research Institute, University of Adelaide
  191. Guy's Hospital, London
  192. Harvard’s Bussey Institute 
  193. Heidelberg University Hospital
  194. Hercules Capital
  195. Hitachi Chemical
  196. Hong Kong Institute of Biotechnology
  197. Hookipa Biotech
  198. Hope Center Viral Vectors Core, Washington University School of Medicine
  199. Horizon Discovery 
  200. Hospital de Sant Pau
  201. Hubei Tongji Benda Ebei Pharmaceutical
  202. Human Gene and Cell Therapy Center, Akdeniz University
  203. Human Stem Cells Institute
  204. ID Pharma (previously known as DNAVEC)
  205. Immune Design
  206. Immune Technology
  207. ImmunoGenes
  208. Immunomic Therapeutics
  209. IMSUT Hospital
  210. Inbiomed 
  211. Indiana University Vector Production Facility 
  212. Instituto de Tecnologia Química e Biológica António Xavier
  213. Intrexon 
  214. InvivoGen
  215. IPPOX Foundation
  216. IQVIA Stem Cell Center 
  217. IRBM
  218. Janelia Research Campus
  219. Janssen
  220. Jichi Medical University Hospital 
  221. Kalon Biotherapeutics 
  222. Kaneka Eurogentec
  223. Keensight Capital 
  224. Kelley School of Business, Indiana University
  225. King's College London, Guy's and St Thomas' NHS Foundation Trust
  226. Kite Pharma
  227. Kobe Biomedical Innovation Cluster
  228. Kolon Life Sciences
  229. Krystal Biotech
  230. Laboratory of Malaria Immunology and Vaccinology
  231. LakePharma
  232. Lentigen Technology
  233. Lentiviral Lab, USC School of Pharmacy
  234. Leuven Viral Vector Core
  235. Lonza
  236. Luminous BioSciences
  237. Lund University
  238. Lysogene
  239. Massachusetts Eye and Ear 
  240. Massachusetts General Hospital Neuroscience Center
  241. Massachusetts Life Science Center
  242. MassBiologics 
  243. MaSTHerCell
  244. MaxCyte
  245. Medigene
  246. MedImmune (AstraZeneca)
  247. MeiraGTx
  248. Merck 
  249. Merck Serono
  250. Merial
  251. Michael J. Fox Foundation for Parkinson Research
  252. Microsoft Research 
  253. Mie University Hospital
  254. Mila's Miracle Foundation
  255. MilliporeSigma
  256. Miltenyi Biotec
  257. Ministry of Economy and Competitiveness
  258. Mitsubishi 
  259. MoBiTec
  260. Molecular Diagnostic Services
  261. Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University
  262. MolMed
  263. Myeloma Crowd Research Initiative 
  264. NanoCor Therapeutics 
  265. Nantes Gene Therapy Institute 
  266. National Cancer Institute
  267. National Center for Advancing Translational Sciences
  268. National Human Genome Research Institute 
  269. National Institute of Neurodegenerative Disorders and Stroke Center Core, University of Minnesota
  270. National Institutes of Health
  271. National Virus Vector Laboratory, University of Eastern Finland
  272. Nature Technology
  273. Naval Medical Research Center 
  274. Neuroscience CenterVector Core, Massachusetts General Hospital 
  275. Neuroscience Gene Vector and Virus Core, Stanford Medicine
  276. NewLink Genetics
  277. Nikon CeLL innovation
  278. Nouscom
  279. Novartis
  280. Novasep
  281. Novo Holdings 
  282. Oaktree Capital Management
  283. Ocular Gene Therapy Core, National Eye Institute
  284. Odylia
  285. Okairos 
  286. Okayama University Hospital
  287. Omnia Biologics
  288. Orchard Therapeutics
  289. Oregenesis
  290. Oxford BioMedica 
  291. Oxford Genetics 
  292. PacificGMP 
  293. Pall Biotech
  294. Paragon Bioservices
  295. Paragon Gene Therapy 
  296. Penn Vector Core, University of Pennsylvania
  297. PeriphaGen
  298. Pfizer
  299. PharmaCell
  300. PharmaChem Technologies
  301. pHion Therapeutics
  302. Pinchal & Company
  303. PlasmidFactory
  304. Platinum Equity
  305. PLT SCIENTIFIC 
  306. PolyPeptide Laboratories Holding 
  307. Powell Gene Therapy Center, University of Florida
  308. Precigen
  309. ProBioGen
  310. Prolog Venture
  311. ProMab Biotechnologies
  312. Protein Sciences 
  313. Provecs Medical
  314. Puresyn
  315. Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia
  316. Rayne Cell Therapy Suite, King's College London
  317. REGENXBIO
  318. Renova Therapeutics
  319. Rentschler Biotechnologie
  320. Repligen 
  321. Richter-Helm BioLogics
  322. RIKEN BioResource Research Center
  323. Roche
  324. Rock Springs Capital
  325. Rocket Pharmaceuticals
  326. Rubius Therapeutics
  327. SAB-Technology
  328. San Raffaele Scientific Institute
  329. Sangamo Therapeutics 
  330. Sanofi CEPiA (now Sanofi Active Ingredients Solutions)
  331. Sanofi Genzyme
  332. Sanofi Pasteur
  333. Santen Pharmaceutical
  334. Sarepta Therapeutics 
  335. Sartorius Stedim Biotech
  336. Scancell 
  337. Scarab Genomics 
  338. Selecta Biosciences
  339. Servier
  340. Shanghai Sunway Biotech
  341. Shenzhen SiBiono GeneTech
  342. Shire
  343. Sigma-Aldrich (SAFC)
  344. SignaGen Laboratories
  345. SillaJen 
  346. Sino Biological 
  347. SIRION Biotech
  348. Sofinnova Ventures
  349. Spark Therapeutics
  350. St Thomas' NHS Foundation Trust 
  351. Stevenage Bioscience Catalyst
  352. Strathmann Biotec 
  353. Stratophase
  354. Symbiosis Pharmaceutical Services 
  355. Synpromics
  356. Synthace
  357. Synthetic Genomics
  358. System Biosciences
  359. T. Rowe Price Associates
  360. TangenX Technology 
  361. TCR2 Therapeutics 
  362. Tecrea
  363. Telethon Foundation 
  364. Terry Fox Laboratory
  365. Texas A&M University
  366. The Finnish Fair Foundation
  367. The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Organization
  368. The Jarvis Lab
  369. The Lentiviral Laboratory, USC School of Pharmacy
  370. The Wellcome Trust / BRC Clinical Research Facility and Cell Therapy Unit (CTU), King’s College London
  371. TheraBiologics
  372. THERAVECTYS
  373. Therexsys
  374. Thermo Fisher Scientific
  375. TissueGene
  376. Touchlight Genetics
  377. Transgene
  378. Treeway
  379. Twist Bioscience
  380. TxCell
  381. UAB Vector Production Facility
  382. uniQure
  383. Unit Biotech & ATMP’s, University Medical Center Groningen
  384. UniTech Pharma 
  385. University of Florida
  386. University of Iowa Research Foundation 
  387. University of Liège 
  388. University of Massachusetts Medical School System 
  389. University of Oxford Clinical BioManufacturing Facility
  390. University of Virginia School of Medicine
  391. Vaccibody
  392. Vaccine and Gene Therapy Institute 
  393. Vaccitech
  394. Valneva
  395. VBI Vaccine 
  396. Vectalys
  397. Vector Biolabs
  398. Vector Core / GMP Facility, UC Davis Health
  399. Vector Core of Gene Therapy, Laboratory of Nantes
  400. Vector Core, Harvard Gene Therapy Initiative
  401. Vector Core, Telethon Institute of Genetics and Medicine
  402. Vector Core, University of Michigan Medical School 
  403. Vector Core, University of North Carolina
  404. Vector Development and Production Facility, Roswell Park Comprehensive Cancer Center
  405. Vector Development Core Laboratory, UC San Diego School of Medicine
  406. Vector Production Facility, Indiana University
  407. Vecura GMP Laboratory, Karolinska Institutet
  408. VGXI
  409. Vibalogics
  410. Vical
  411. Vigene Biosciences
  412. Vineti
  413. Viral Core Facility, NeuroCure
  414. Viral Core, Seattle Children's Research Institute
  415. Viral Gene Transfer Core, Massachusetts Institute of Technology
  416. Viral Vector and Cloning Core, University of Minnesota
  417. Viral Vector Core / Clinical Manufacturing Facility, Nationwide Children's Hospital
  418. Viral Vector Core Facility, University of Iowa Carver College of Medicine
  419. Viral Vector Core Laboratory, National Institute of Environmental Health Sciences
  420. Viral Vector Core Laboratory, The University of Tennessee Health Science Center
  421. Viral Vector Core, Duke University
  422. Viral Vector Core, Emory University School of Medicine
  423. Viral Vector Core, Maine Medical Research Institute
  424. Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute
  425. Viral Vector Core, The Jackson Laboratory
  426. Viral Vector Core, The Jenner Institute
  427. Viral Vector Core, University of Massachusetts Medical School 
  428. Viral Vector Core, University of South Carolina School of Medicine
  429. Viral Vector Facility, Neuroscience Center Zurich
  430. Viral Vector Production Laboratory, Mayo Clinic Cancer Center
  431. Viral Vector Production Unit, Universitat Autònoma de Barcelona-Vall d'Hebrón Institut de Recerca
  432. Viral Vectors Laboratory, Louisiana State University School of Veterinary Medicine
  433. ViralGEN
  434. ViraQuest
  435. ViroMed
  436. Virovek
  437. VirusTech Core Facility, Karolinska Institutet
  438. Vivante GMP Solutions
  439. VIVEbiotech
  440. Vivet Therapeutics
  441. Voyager Therapeutics
  442. Waisman Biomanufacturing
  443. Washington University
  444. Weber Laboratory, Icahn School of Medicine at Mount Sinai
  445. Wellington Management 
  446. West Biotherapy (also known as EFS Atlantic Bio GMP)
  447. Wolfson Gene Therapy Unit, University College of London
  448. WuXi AppTec
  449. Xpress Biologics
  450. Yposkesi
  451. Ziopharm Oncology  

Segmentation

Close to USD 2 billion (by 2030) financial opportunity within the vector manufacturing market has been analyzed across the following segments:

  • Type of Vector
    • AAV
    • Adenoviral
    • Lentiviral
    • Retroviral
    • Plasmid DNA
    • Other Vectors
  • Application
    • Gene Therapy
    • T-Cell Therapy
    • Vaccines
  • Therapeutic Area
    • Oncological Disorders
    • Inflammation & Immunological Disorders
    • Neurological Disorders
    • Ophthalmological Disorders
    • Muscle Disorders
    • Metabolic Disorders
    • Cardiovascular Disorders
    • Others 
  • Scale of Operation
    • Preclinical
    • Clinical
    • Commercial
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com